Healthcare entity
ATG-022 is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. That works out to roughly 0.7 stories per week across a 19-day span. Each story carries 2 original sources on average, compared with 2.3 for the broader beat in this window.
Last mentioned: 4h ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
ATG-022 is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. That works out to roughly 0.7 stories per week across a 19-day span. Each story carries 2 original sources on average, compared with 2.3 for the broader beat in this window. The 5 average consequence score is below the beat benchmark of 5.5 in the same window. health-it accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. Evercore appears in 2 tracked Healthcare stories published from August 5, 2026 through August 23, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 209 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Evercore. Shared-story counts are live from our verified record — not editorial picks.
Press Release Distribution
Company issues PRNewswire release summarizing the summit highlights.
Evercore Summit Presentation
Antengene presents R&D updates including ATG-022 clinical data, TriGager TCE platform, multiple functional modules, and ATG-207 during a fireside chat.
For healthcare executives and clinical leaders, Antengene's R&D showcase highlights emerging targeted oncology and autoimmune candidates. The presentation included updated ATG-022 data and a first-in-class bifunctional fusion protein, signaling pipeline expansion that could eventually affect treatment options. Clinical teams should note the data remain limited and are not yet peer-reviewed.
Teva Pharmaceutical's FY2026 EPS guidance fell short of the $2.17 consensus, while revenue projections of $16.5-$16.9B matched expectations. For healthcare leaders, the miss underscores ongoing generic drug pricing pressures and the importance of a diversified pipeline.
Evercore is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
